Literature DB >> 19586593

The management of sickle cell pain.

Robert E Richard1.   

Abstract

Treatment of pain in the setting of sickle cell disease remains unsatisfactory. The approach remains to treat the pain symptomatically with escalating doses of non-opioid and opioid medications while any underlying inciting process is investigated. For the majority of patients with sickle cell disease, pain will always be part of their lives. Advances in the treatment of sickle cell pain will depend on multiple approaches, including both pharmacologic and nonpharmacologic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586593     DOI: 10.1007/s11916-009-0047-4

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  25 in total

1.  Optimism predicting daily pain medication use in adolescents with sickle cell disease.

Authors:  Laura Pence; Cecelia R Valrie; Karen M Gil; Rupa Redding-Lallinger; Charles Daeschner
Journal:  J Pain Symptom Manage       Date:  2007-03       Impact factor: 3.612

Review 2.  Hydroxyurea for the treatment of sickle cell anemia.

Authors:  Orah S Platt
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

Review 3.  Pathogenesis and treatment of sickle cell disease.

Authors:  H F Bunn
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

4.  Thrombophilia in sickle cell disease: the red cell connection.

Authors:  B N Setty; A K Rao; M J Stuart
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

Review 6.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

7.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

8.  Pain management in sickle cell disease: palliative care begins at birth?

Authors:  Lennette Benjamin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

9.  Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.

Authors:  Eduard J van Beers; Charlotte F J van Tuijn; Pythia T Nieuwkerk; Philip W Friederich; Jan H Vranken; Bart J Biemond
Journal:  Am J Hematol       Date:  2007-11       Impact factor: 10.047

10.  Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.

Authors:  Sherri A Zimmerman; William H Schultz; Shelly Burgett; Nicole A Mortier; Russell E Ware
Journal:  Blood       Date:  2007-04-11       Impact factor: 22.113

View more
  1 in total

1.  Sensitization of nociceptors by prostaglandin E2-glycerol contributes to hyperalgesia in mice with sickle cell disease.

Authors:  Iryna A Khasabova; Megan Uhelski; Sergey G Khasabov; Kalpna Gupta; Virginia S Seybold; Donald A Simone
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.